Modern Multiple Myeloma Care: Trials to Clinical Practice
Evolving Paradigm of Plasma Cell Disorders
Rapid advances in immunotherapy and cellular engineering have fundamentally transformed multiple myeloma treatment. Historically, clinicians viewed myeloma as an incurable malignancy with a survival of only a few years. Today, modern induction regimens and novel cellular platforms allow physicians to pursue durable functional cures. However, the rapid emergence of diverse therapeutic classes introduces clinical complexity for practicing oncologists. Therefore, establishing a systematic, evidence-based decision framework has become vital for routine clinical practice.
First-Line Multiple Myeloma Treatment Protocols
Therapy for newly diagnosed multiple myeloma now begins with aggressive multi-agent combinations. Specifically, quadruplet induction regimens combining an anti-CD38 antibody, proteasome inhibitor, immunomodulatory drug, and dexamethasone represent standard care. In addition, baseline risk stratification using cytogenetics, clinical stages, and patient fitness guides these initial treatment decisions. Clinicians must carefully evaluate patient frailty before escalating systemic toxicity. Furthermore, investigators are currently reevaluating the role of autologous stem cell transplantation in patients achieving deep responses.
Assessing Minimal Residual Disease and Relapse
Modern protocols increasingly rely on measurable residual disease status to judge therapeutic depth and forecast relapse. Consequently, achieving sustained MRD negativity at high sensitivity serves as an essential clinical benchmark. Moreover, early disease interception strategies show promise in patients with high-risk smoldering myeloma. When overt clinical relapse occurs, clinicians must navigate complex targeted immune therapies. For example, oncologists must carefully sequence CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. Furthermore, physicians must evaluate T-cell fitness and multi-antigen strategies to counter exhaustion and tumor escape.
Frequently Asked Questions
Q1: What defines standard induction in newly diagnosed multiple myeloma?
Standard frontline care typically uses a quadruplet regimen combining an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, and dexamethasone.
Q2: How does measurable residual disease guide clinical decisions?
Tracking measurable residual disease helps clinicians assess therapeutic depth, evaluate remission durability, and consider personalized modifications to maintenance protocols.
Q3: Which strategies address relapse after BCMA-targeted therapy?
Physicians counter relapse through multi-antigen targeting, sequential bispecific antibodies, antibody-drug conjugates, and clinical trial enrollment to overcome immune exhaustion.
References
- Mouhieddine TH et al. Treatment Decisions in Multiple Myeloma. N Engl J Med. 2026 Sep 10. doi: 10.1056/NEJMra2605253. PMID: 42715563.
- Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322.
- Kumar SK, Callander NS, Adekola K, et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(12):1287-1301.
